EXELON (rivastigmine tartrate)
EXELON is indicated for the treatment of Alzheimer's Disease; Parkinson's Disease Dementia.
How EXELON Works
Rivastigmine is thought to exert its therapeutic effect by enhancing cholinergic function. It increases the concentration of acetylcholine by reversibly inhibiting cholinesterase, the enzyme responsible for breaking it down. By preventing this hydrolysis, the drug facilitates improved communication between neurons. The effectiveness of this mechanism may diminish as the disease advances and fewer cholinergic neurons remain intact.
Development Insights
Details
- Status
- Discontinued
- First Approved
- 2000-04-21
- Routes
- ORAL, TRANSDERMAL
- Dosage Forms
- SOLUTION, CAPSULE, FILM, EXTENDED RELEASE
EXELON Approval History
What EXELON Treats
2 indicationsEXELON is approved for 2 conditions since its original approval in 2000. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Alzheimer's Disease
- Parkinson's Disease Dementia
EXELON Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to EXELON
3 of 10FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
1 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT01340885 results posted | PANUC - Lou 5P50NS062684-02 | Ph 4 | completed | Cognitive Decline in Non-demented PD |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
EXELON FDA Label Details
Indications & Usage
FDA Label (PDF)EXELON is indicated for the treatment of Alzheimer's Disease; Parkinson's Disease Dementia.
Explore on TheraRadar
Alzheimer's Disease Drug Landscape 2026
Disease-modifying therapies, symptomatic treatments, and clinical trial intelligence
Related Intelligence
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment